-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GxOZv/TbeYdQtDyoG5FdJyrQigiczD9cS5H2cQLjUuMd/NqDY88htGcm2AXWAR1W VaHjcyBCNdV8weHnCyLM0g== 0001005477-97-001142.txt : 19970425 0001005477-97-001142.hdr.sgml : 19970425 ACCESSION NUMBER: 0001005477-97-001142 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19970331 FILED AS OF DATE: 19970424 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVOSTE CORP /FL/ CENTRAL INDEX KEY: 0001012131 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 592787476 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20727 FILM NUMBER: 97586602 BUSINESS ADDRESS: STREET 1: 4350-C INTERNATIONAL BLVD CITY: NORCROSS STATE: GA ZIP: 30093 BUSINESS PHONE: 7707170904 MAIL ADDRESS: STREET 1: 4350 C INTERNATIONAL BLVD CITY: NORCROSS STATE: GA ZIP: 30093 10-Q 1 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q |X| Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 1997. |_| Transition period pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____________ to ______________. 0-20727 ------- (Commission File Number) Novoste Corporation ------------------- (Exact Name of Registrant as Specified in Its Charter) Florida 59-2787476 ------- ---------- (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 4350-C International Blvd., Norcross, GA 30093 ---------------------------------------- ----- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone, including area code: (770) 717-0904 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such requirements for the past 90 days. (Item 1) Yes |X| No |_| (Item 2) Yes |X| No |_| As of March 31, 1997, there were 8,430,375 shares of the Registrant's Common Stock outstanding. Exhibit Index on page: 14 Total number of pages: 16 1 NOVOSTE CORPORATION FORM 10-Q INDEX PART I. FINANCIAL INFORMATION PAGE NO. -------- Item 1. Condensed Financial Statements Condensed Balance Sheets as of March 31, 1997 (unaudited) and December 31, 1996 3 Condensed Statements of Operations (unaudited) for the three months ended March 31, 1997 and 1996 and the period from inception (May 22, 1992) through March 31, 1997 4 Condensed Statements of Cash Flows (unaudited) for the three months ended March 31, 1997 and 1996 and the period from inception (May 22, 1992) through March 31, 1997 5 Notes to Condensed Financial Statements 6-7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 8-11 PART II. OTHER INFORMATION Item 5. Other Information 12 Item 6. Exhibits and Reports on Form 8-K 12 SIGNATURES 13 EXHIBIT INDEX 11 EXHIBIT 11 - COMPUTATION OF NET LOSS PER SHARE EXHIBIT 27 - FINANCIAL DATA SCHEDULE 2 NOVOSTE CORPORATION (A Development Stage Company) CONDENSED BALANCE SHEETS
March 31, December 31, 1997 1996 ------------ ------------ (unaudited) Assets Current assets: Cash and cash equivalents $ 17,572,395 $ 19,954,827 Short-term investments 7,753,093 7,588,693 Prepaid expenses 83,808 126,349 ------------ ------------ Total current assets 25,409,296 27,669,869 Property and equipment, net 1,108,329 1,128,031 License agreements, net 149,987 153,396 Other assets 159,884 303,642 ------------ ------------ $ 26,827,496 $ 29,254,938 ============ ============ Liabilities and shareholders' equity Current liabilities: Accounts payable $ 321,106 $ 155,946 Accrued expenses and taxes withheld 502,551 665,175 ------------ ------------ Total current liabilities 823,657 821,121 ------------ ------------ Shareholders' equity: Preferred stock, $.01 par value, 5,000,000 shares authorized; no shares issued and outstanding -- -- Common stock, $.01 par value, 25,000,000 shares authorized; 8,435,655 and 8,257,967 issued, respectively 84,356 82,580 Additional paid-in capital 41,983,443 41,772,791 Deficit accumulated during the development stage (16,048,120) (13,405,714) ------------ ------------ 26,019,679 28,449,657 Less treasury stock, 5,280 shares of common stock, at cost (15,840) (15,840) ------------ ------------ Total shareholders' equity 26,003,839 28,433,817 ------------ ------------ $ 26,827,496 $ 29,254,938 ============ ============
See accompanying notes. 3 NOVOSTE CORPORATION (A Development Stage Company) UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
From inception Three months ended (May 22, 1992) March 31, through March 31, 1997 1996 1997 -------------------------- ----------------- Revenues: Miscellaneous sales $ -- $ -- $ 290,887 Costs and expenses: Research and development 2,323,838 884,063 11,210,870 General and administrative 517,098 176,965 4,604,639 Marketing 138,530 119,408 1,670,641 ----------- ----------- ------------- 2,979,466 1,180,436 17,486,150 ----------- ----------- ------------- Loss from operations (2,979,466) (1,180,436) (17,195,263) ----------- ----------- ------------- Interest income 337,060 7,256 1,328,902 Interest expense (37,481) (181,759) ----------- ----------- ------------- Net loss $(2,642,406) $(1,210,661) $ (16,048,120) =========== =========== ============= Net loss per share $ (0.32) $ (0.24) ========== =========== Weighted average shares outstanding 8,330,281 4,947,222 ========== ===========
See accompanying notes. 4 NOVOSTE CORPORATION (A Development Stage Company) UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS
From inception For the three months (May 22, 1992) ended March 31, through March 31, 1997 1996 1997 ------------- ----------- ----------------- Cash flows from operating activities Net loss $ (2,642,406) $(1,210,661) $(16,048,120) Adjustments to reconcile net loss to net cash used by operating activities: Depreciation and amortization 99,060 70,217 976,935 Issuance of stock for services or compensation 67,500 139,511 1,014,818 Changes in assets and liabilities: Prepaid expenses 42,541 (27,237) (91,267) Accounts payable 165,160 85,266 321,106 Accrued expenses and taxes withheld (162,624) (19,934) 897,058 ------------ ----------- ------------ Net cash used by operations (2,430,769) (962,838) (12,929,470) ------------ ----------- ------------ Cash flows from investing activities Purchase of short-term investments (164,400) -- (7,753,093) Purchase of property and equipment, net (62,910) (83,081) (1,815,336) Other 130,719 -- (225,318) ------------ ----------- ------------ Net cash used by investing activities (96,591) (83,081) (9,793,747) ------------ ----------- ------------ Cash flows from financing activities Proceeds from issuance of notes payable -- 1,800,000 4,770,150 Repayment of notes payable -- -- (2,970,150) Proceeds from issuance of common stock 144,928 57,540 38,227,394 Exercise of warrants -- -- 268,218 ------------ ----------- ------------ Net cash provided by financing activities 144,928 1,857,540 40,295,612 ------------ ----------- ------------ Net (decrease) increase in cash and cash equivalents (2,382,432) 811,621 17,572,395 Cash and cash equivalents at beginning of period 19,954,827 817,587 -- ------------ ----------- ------------ Cash and cash equivalents at end of period $ 17,572,395 $ 1,629,208 $ 17,572,395 ============ =========== ============ Supplemental disclosures of cash flow information Cash paid for interest -- $ 8,986 $ 165,137 ============ =========== ============
See accompanying notes. 5 NOVOSTE CORPORATION (A Development Stage Company) NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS March 31, 1997 Note 1. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with instructions to Article 10 of Regulation S-X. Accordingly, such financial statements do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The operating results of the interim periods presented are not necessarily indicative of the results to be achieved for the year ending December 31, 1997. The accompanying financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 1996 and for the cumulative period from May 22, 1992 (inception) through December 31, 1996, included in the Company's 1996 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"). Certain prior year expense amounts have been reclassified in the Statements of Operations for the three months ended March 31, 1996 and the period from inception through March 31, 1997 to conform with current year classifications. Note 2. Net Loss Per Share The net loss per share is computed based on the weighted average number of common shares outstanding after giving effect to certain adjustments described below. Common equivalent shares are not included in the per share calculations where the effect of their inclusion would be antidilutive, except that, in accordance with SEC requirements, common and common stock equivalent shares issued during the twelve-month period prior to the initial filing of the public offering on April 11, 1996 have been included in the calculations as if they were outstanding through March 31, 1996 using the treasury stock method. See Exhibit 11. Historical net loss per share information presented in accordance with GAAP for the periods affected by the above mentioned SEC requirement is as follows: Three months ended March 31, 1996 ---- Net loss per share $ (0.29) ========== Shares used in computing net loss per share 4,110,195 ========== 6 NOVOSTE CORPORATION (A Development Stage Company) NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS March 31, 1997 Note 3. Cash Equivalents and Investments Cash equivalents are comprised of certain highly liquid investments with maturities of less than three months. In addition to cash equivalents, the Company has investments in commercial paper that are classified as short-term (mature in more than 90 days but less than one year). Such investments are classified as held-to-maturity, as the Company has the ability and intent to hold them until maturity. Investments held-to-maturity are carried at amortized cost, adjusted for the amortization or accretion of premiums or discounts without recognition of gains or losses that are deemed to be temporary. Premiums and discounts are amortized or accreted over the life of the related instrument as an adjustment to yield using the straight-line method, which approximates the effective interest method. Interest income is recognized when earned. Fair value approximates carrying value for all cash equivalents and investments. Note 4. Shareholders' Equity On May 20, 1996 the Company amended an option to purchase 100,000 shares of Common Stock at $3.20 per share of which options for 75,000 shares had not yet become exercisable. As amended, options to purchase such 75,000 shares become exercisable at the annual rate of 25,000 shares beginning May 20, 1997, subject to acceleration upon the achievement of three specified milestones at the rate of 25,000 shares per milestone. The Company is recording total non-cash compensation expense of $810,000 ratably over the three year period ending May 19, 1999, subject to acceleration if the specific milestones are met at earlier dates; $67,500 was expensed in the three months ended March 31, 1997 relating to these options. 7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward Looking Information The statements contained in this Form 10-Q that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events and financial performance, but are subject to many uncertainties and risks which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward-looking statements. Examples of such uncertainties and risks include, but are not limited to, whether the Beta-Cath(TM) System, the Company's primary product in development, will prove safe and effective; whether and when the Company will obtain approval of the Beta-Cath(TM) System from the United States Food and Drug Administration ("FDA") and corresponding foreign agencies; the Company's need to achieve manufacturing scale-up in a timely manner, and its need to provide for the efficient manufacturing of sufficient quantities of its products; the Company's dependence on the Beta-Cath(TM) System as the primary source of future revenue; the lack of an alternative source of supply for the radiation source materials used in the Beta-Cath(TM) System; the Company's patent and intellectual property position; the Company's need to develop the marketing, distribution, customer service and technical support and other functions critical to the success of the Company's business plan; the effectiveness and ultimate market acceptance of the Beta-Cath(TM) System; limitations on third party reimbursement; and competition between rival developers of restenosis reduction and other products. The Company does not undertake any obligation to update or revise any forward-looking statement, made by it or on its behalf, whether as a result of new information, future events, or otherwise. Overview Novoste, incorporated in January 1987, was first capitalized and commenced operations in May 1992. To date the Company has been engaged primarily in research and development efforts and clinical trials in interventional cardiology, electrophysiology and critical care products. Commencing in 1994, the Company has devoted its efforts to developing the Beta-Cath(TM) System, an intraluminal beta radiation catheter delivery system designed to reduce the frequency of restenosis subsequent to percutaneous transluminal coronary angioplasty ("PTCA"). The Beta-Cath(TM) System applies localized beta radiation to the site of the vascular injury caused by a PTCA procedure and is designed to inhibit long-term cell proliferation ("hyperplasia") and vascular remodeling, each primary causes of restenosis. The Beta-Cath(TM) System was developed in collaboration with certain physicians at Emory University Hospital, including its Director of Interventional Cardiology, Dr. Spencer B. King, III. The development, manufacture, sale and distribution of medical devices such as the Company's Beta-Cath(TM) System are subject to numerous regulations imposed by governmental authorities, principally the FDA and corresponding state and foreign agencies. The regulatory process is lengthy, expensive and uncertain. FDA approval of a Pre Market Approval ("PMA") application is required before any Beta- 8 Cath(TM) System can be marketed in the United States. Securing FDA approval will require submission to the FDA of extensive clinical data and technical information. The Company does not expect regulatory approval of the Beta-Cath(TM) System for sale in the United States prior to 1999 or for sale outside the United States prior to 1998, and there can be no assurance when or if such approvals will be obtained. The Company conducted a feasibility clinical trial at Emory and Rhode Island Hospital under an Investigational Device Exemption ("IDE") granted by the FDA to determine the clinical safety of the Beta-Cath(TM) System for use in coronary arteries. Patient enrollment for the clinical trial at Emory was completed on July 31, 1996 and the enrollment at Rhode Island was completed on October 25, 1996. Twenty-three patients were enrolled in the study. Six month follow-up has been completed for all patients and preliminary summary data on 18 patients revealed a restenosis rate of 17%. Three patients required target lesion revascularization (a re-opening procedure at the original treatment site) during the six month follow-up. The late loss index (a measure of how much of the angioplasty benefit is lost over six months) was 5%. In addition, no adverse clinical events relating to the Beta-Cath(TM) System were reported. The Company commenced a human clinical safety study at a single site in Canada on February 19, 1997 and anticipates commencing a similar study in The Netherlands by the end of April 1997. In addition, the Company anticipates filing an IDE supplement shortly to perform a multicenter safety and efficacy clinical trial in the United States, which is scheduled to start in the summer of 1997. For the period since its capitalization through March 31, 1997 the Company has earned minimal non-recurring revenues and experienced significant losses in each period. At March 31, 1997 the Company had an accumulated deficit of approximately $16 million. Further, Novoste expects to continue to incur significant operating losses through at least 1998 and expects cumulative losses to increase significantly as the Company continues to initiate new research and development projects, conduct its clinical trials in the United States, Canada and Europe, seek regulatory approval or clearance for its products, expand its sales and marketing efforts in contemplation of product introduction and market development, and increase its administrative activities to support growth of the Company. There can be no assurance that the Company's research and development efforts will be successfully completed. Additionally, as clinical testing is incomplete, there can be no assurance that the Beta-Cath(TM) System will be safe and effective. There can be no assurance that the Beta-Cath(TM) System will be approved by the FDA or any domestic or foreign government agency or that the Beta-Cath(TM) System or any other product developed by Novoste will be successfully introduced or attain any significant level of market acceptance. There can be no assurance that the Company will ever achieve either significant revenues from sales of its Beta-Cath(TM) System or ever achieve or sustain profitability. Results of Operations Net loss for the three months ended March 31, 1997 was $2,642,000, or ($0.32) per share, as compared to $1,211,000, or ($0.24) per share, for the three months ended March 31, 1996. The increase in net loss for the three months ended March 31, 1997 compared to the year earlier period is due to increased spending for research and development and general and administrative expenses related to the Company's development of its Beta-Cath(TM) System, offset by increased interest income earned from the investment of the net proceeds from the initial public offering in May 1996. Revenues. No revenues were earned in the three months ended March 31, 1997 and 1996. 9 Research and Development Expenses. Research and development expenses increased 163% to $2,324,000 for the three months ended March 31, 1997 from $884,000 for the three months ended March 31, 1996. These increases were primarily a result of increased services provided by outside consultants in the development of the Beta-Cath(TM) System, and the reimbursement of development costs incurred by the Company's radioactive isotope supplier. The Company expects research and development expenses to continue to increase in the future as the Company initiates additional clinical trials of its Beta-Cath(TM) System in both the U.S. and selected foreign countries, and it continues the development and design of the Beta-Cath(TM) System and component parts. General and Administrative Expenses. General and administrative expenses increased 192% to $517,000 for the three months ended March 31, 1997 from $177,000 for the three months ended March 31, 1996. These increases were primarily a result of additional personnel, higher salaries and increased costs associated with being a public company such as directors and officers liability insurance and legal and accounting fees. The Company expects general and administrative expenses to increase in the future in support of a higher level of operations. Marketing Expenses. Marketing expenses increased 17% to $139,000 for the three months ended March 31, 1997 from $119,000 for the three months ended March 31, 1996. These increases were primarily a result of increased trade show costs and higher salaries. The Company expects sales and marketing expenses to significantly increase in the future, if and when the Beta-Cath(TM) System is approved in the U.S. and other countries. Interest Income. Net interest income increased to $337,000 for the three months ended March 31, 1997 whereas net interest expense of $30,000 was incurred during the three months ended March 31, 1996. The increase in interest income was primarily due to the closing of the Company's initial public offering resulting in larger cash equivalents and short-term investment balances. Liquidity and Capital Resources The Company financed its activities since inception up to May 29, 1996, the date of the Company's initial public offering, through private placements of its Common Stock, Class B Common Stock and promissory notes. Since inception through March 31, 1997, the Company obtained funds aggregating approximately $38.2 million in net proceeds from the issuance of Common Stock and Class B Common Stock (including approximately $30.6 million in net proceeds from its initial public offering which closed in May 1996), and approximately $1.8 million in net proceeds from the issuance of convertible promissory notes. During the three months ended March 31, 1997 and 1996, the Company used cash to fund operations of $2.4 million and $1.0 million, respectively. Cash used to fund operations since inception was approximately $12.9 million. The increase in cash used in operations was due primarily to higher expenses associated with increased research and development activities and increased general and administrative expenses to support increased operations. The Company's expenditures for equipment and improvements have aggregated $1.8 million since inception. Future cash needs for operating activities are 10 anticipated to be higher than historical levels because of the development, manufacturing scale-up and commercialization of the Beta-Cath(TM) System, subject to the factors discussed above. The Company's principal source of liquidity at March 31, 1997 consisted of cash, cash equivalents and short-term investments of $25.3 million. The Company did not have any credit lines available or outstanding borrowings at March 31, 1997. The Company anticipates that its operating losses will continue through at least 1998 because it plans to expend substantial resources in funding clinical trials in support of regulatory approvals, and continues to expand research and development and marketing activities. Novoste believes that current cash balances and short-term investments, together with interest thereon, will be sufficient to meet the Company's operating and capital requirements through calendar 1997. However, the Company's future liquidity and capital requirements will depend upon numerous factors, including the progress of the Company's clinical research and product development programs; the receipt of and the time required to obtain regulatory clearances and approvals; the resources required to gain approvals; the resources the Company devotes to the development, manufacture and marketing of its products; the resources required to hire and develop a direct sales force in the United States, develop distributors internationally, and to expand manufacturing capacity; facilities requirements; market acceptance and demand for its products; and other factors. Novoste may in the future seek to raise additional funds through bank facilities, debt or equity offerings or other sources of capital. There can be no assurance that additional financing, if required, will be available on satisfactory terms, or at all. New Accounting Pronouncements In February 1997 the Financial Accounting Standards Board issued a new accounting pronouncement, SFAS No. 128, "Earnings per Share", which will change the current method of computing earnings per share. The new standard requires presentation of "basic earnings per share" and "diluted earnings per share" amounts, as defined. SFAS No. 128 will be effective for the Company's quarter and year ending December 31, 1997, and, upon adoption, all prior-period earnings per share data presented shall be restated to conform with the provisions of the new pronouncement. Application earlier than the Company's quarter ending December 31, 1997 is not permitted. 11 PART II. OTHER INFORMATION Item 5. Other Information Jonathan J. Rosen resigned as Vice President - Product Development of the Company effective February 28, 1997. Also on February 28, 1997 Charles E. Larsen was promoted to Chief Technical Officer from his previous position as Chief Operating Officer, and David N. Gill was promoted to Chief Operating Officer. David Gill will continue as Vice President - Finance and Chief Financial Officer. Item 6. Exhibits and Reports on Form 8-K (a) The following exhibits are included herein: (11) Computation of net loss per share (27) Financial data schedule (b) The Company did not file any reports on Form 8-K during the three months ended March 31, 1997. 12 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVOSTE CORPORATION April 23, 1997 s/Thomas D. Weldon - ----------------------------------- ------------------------------------------ Date Thomas D. Weldon President & Chief Executive Officer April 23,1997 s/David N. Gill - ----------------------------------- ------------------------------------------ Date David N. Gill Vice President - Finance, Chief Operating Officer and Chief Financial Officer (Principal Financial & Accounting Officer) 13 EXHIBIT INDEX Exhibit Page Number Exhibit Description Number - ------- ------------------------------------ ------ 11 Computation of net loss per share 27 Financial data schedule 14 EX-11 2 COMPUTATION OF NET LOSS PER SHARE Novoste Corporation Exhibit 11 Computation of Net Loss Per Share Three Months Ended March 31, ------------------------- 1997 1996 ------------------------- Weighted average number of shares of common stock outstanding during the year 8,330,281 4,110,195 Effect of common stock issued and stock options and warrants granted during the 12- month period preceding April 11, 1996 (1) -- 1,194,411 Elimination of duplicative effect of including the same shares in both above amounts -- (357,384) ----------- ----------- Total common and common equivalent shares 8,330,281 4,947,222 =========== =========== Net loss $(2,642,406) $(1,210,661) =========== =========== Net loss per share (2) $ (0.32) $ (0.24) =========== =========== (1) Pursuant to Securities and Exchange Commission Staff Accounting Bulletin No. 83, Common Stock issued and stock options and warrants granted at prices below the initial public offering price per share during the 12-month period immediately preceding the initial filing date of the Company's Registration Statement for its initial public offering have been included as outstanding for all periods presented which include periods prior to such filing date using the treasury stock method. (2) Since the impact of including common stock equivalents is anti-dilutive for both primary and fully diluted loss per share, the calculation of loss per share for both purposes is identical. EX-27 3 FDS -- NOVOSTE CORPORATION
5 3-MOS DEC-31-1997 JAN-01-1997 MAR-31-1997 17,572,395 7,753,093 0 0 0 25,409,296 1,793,782 (685,453) 26,827,496 823,657 0 0 0 84,356 25,919,483 26,827,496 0 0 0 (2,979,466) 0 0 337,060 (2,642,406) 0 (2,642,406) 0 0 0 (2,642,406) (0.32) (0.32)
-----END PRIVACY-ENHANCED MESSAGE-----